Undifferentiated Pleomorphic Sarcoma
25
6
10
7
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
4.0%
1 terminated out of 25 trials
87.5%
+1.0% vs benchmark
0%
0 trials in Phase 3/4
43%
3 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (25)
A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg
Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery
Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma
Prospective Identification of Predictive Biomarkers of Trabectedin Efficacy in Non-L Soft-tissue Sarcoma Patients
Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery
Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas
Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas
CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma
Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas
A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas
Focused Ultrasound to Promote Immune Responses for Undifferentiated Pleomorphic Sarcoma
MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma
Evaluation of Chest CT Versus Chest X-Ray for Lung Surveillance After Curative-Intent Resection of High-Risk Truncal-Extremity Soft Tissue Sarcoma
A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)
ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma
Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma
Propranolol and Pembrolizumab in Advanced Soft Tissue Sarcoma Patients
Registry For Children, Adolescents And Adults With Osteosarcoma And Biologically Related Bone Sarcomas
Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma
A Study of LY3435151 in Participants With Solid Tumors